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background: Patients with heart failure have abnormal endothelial function. Although use of a continuous flow left ventricular assist device (LVAD) 
results in significant hemodynamic improvement, the effects on systemic endothelial function are unclear.
Methods: We measured reactive hyperemia index (RHI) to evaluate sequential change in endothelial functions using peripheral arterial tonometry 
at the following intervals: before, 5-10 days after (early postoperative), 4-6 weeks after (1st follow up), and 3-7 months after (2nd follow up) 
implantation of continuous flow LVAD. Patients were followed clinically for the occurrence of an adverse cardiovascular event, a composite of death, 
thrombosis, bleeding, heart failure, renal failure, and arrhythmia.
results: Eighteen heart failure patients with LVAD implantations were included. RHI was significantly decreased after operation (Figure). The 
decrease in early post-operative RHI relative to pre-operative RHI was associated with adverse cardiovascular events (age adjusted risk ratio for 
0.25 decrease in RHI 1.35, 95 % confidence interval 1.13 to 1.62, p=0.001).
conclusion: This study demonstrated a significant and persistent decline in peripheral endothelial function up to five months following 
implantation of continuous flow LVAD, and this decline was associated with adverse cardiovascular events. These findings may provide insight into 
some of the vascular complications following continuous flow LVAD therapy in heart failure patients.
 
